Boston Scientific raises FY23 adjusted EPS view to $1.96-$2.00 from $1.90-$1.96

Consensus $1.95. Raises FY23 revenue view to 10.5%-11.5% from 8.5%-10.5%, consensus $13.95B. The company said, “The company now estimates net sales growth for the full year 2023, versus the prior year period, to be approximately 10.5 to 11.5 percent on a reported basis, and approximately 10 to 11 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates EPS on a GAAP basis in a range of $0.87 to $0.93 and estimates adjusted EPS, excluding certain charges (credits), of $1.96 to $2.00.”